A prospective non-randomised, multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies
Trial Overview and Summary
| Chief Investigator: |
Professor Daniel Rea |
|---|
| Sponsor: |
University of Birmingham |
|---|
| Funder: |
CRUK and BiSTC |
|---|
| Disease Site: |
Breast |
|---|
| Trial Type: |
Feasibility Study |
|---|
| Status: |
Open to recruitment |
|---|
| UKCRN Study ID: |
38071 |
|---|
| Open to New Sites? |
Yes |
|---|
| Recruitment Start Date: |
May 2019 |
|---|
| Anticipated Recruitment End Date: |
End of December 2023 |
|---|
| CRCTU Trial Management Team: |
B Team |
|---|
| Trial Email Address: |
nostra@trial.bham.ac.uk |
|---|
Trial Summary
A prospective non-randomised, single-arm, multicentre, feasibility study for a proposed future randomised phase III clinical trial. To determine whether patients with residual cancer can be identified by histological examination of multiple US-guided tumour bed core biopsies following dual-targeted neoadjuvant treatment for HER2-positive, ER-negative early primary breast cancer.
- NOSTRA Trial Summary v3.0 29-Jan-2020
Trial Protocol (login required)
- NOSTRA Protocol Version 3.0 29-Jan-2020 [pdf]
More Information